MapLight Therapeutics, Inc.(MPLT)
$7.07-0.41 (-5.48%)
MPLT
MapLight Therapeutics, Inc. stock forecast
$7.07
At close:-0.41 (-5.48%)
Want to see MPLT full AI Analyst Report?
MapLight Therapeutics, Inc. (MPLT) Stock Forecast & Price Target
37 Followers
MPLT Analyst Ratings
Moderate Buy
2Buy2Hold0Sell
Based on 4 analysts giving stock ratings to MapLight Therapeutics, Inc. in the past 3 months
MPLT Stock 12 Month Forecast
Average Price Target
$33.67▲(376.19% Upside)Based on 4 Wall Street analysts offering 12 month price targets for MapLight Therapeutics, Inc. in the last 3 months. The average price target is $33.67 with a high forecast of $43.00 and a low forecast of $21.00. The average price target represents a 376.19% change from the last price of $7.07.
Past 12 Months12 Month ForecastJan2026Oct2026
High$43.00
Average$33.67
Low$21.00
Highest Price TargetHighest$43.00Average Price Target$33.67Lowest Price TargetLowest$21.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Delma Caiati | Guggenheim | ― | hold | ― | Initiated | 10/05/26 | ||
| Ami Fadia | Needham | $45→$43 | buy | 508.20%Upside | Assigned | 08/31/26 | ||
| Sean Laaman | Morgan Stanley | $21 | hold | 197.03%Upside | Assigned | 08/17/26 | ||
| Francois Brisebois | LifeSci Capital | $37 | buy | 423.34%Upside | Reiterated | 08/14/26 | ||
| Evan Seigerman | BMO Capital | $46→$20 | buy | 182.89%Upside | Reiterated | 08/13/26 | ||
| Ashwani Verma | UBS | $52→$13 | hold | 83.88%Upside | Downgraded | 08/11/26 | ||
 Unknown AnalystNot Ranked | Jefferies | $25 | buy | 253.61%Upside | Reiterated | 07/30/26 | ||
| Ram Selvaraju | H.C. Wainwright | $45→$26 | buy | 267.75%Upside | Reiterated | 07/28/26 | ||
| Adam Vogel | Craig-Hallum | $40→$25 | buy | 253.61%Upside | Reiterated | 07/28/26 | ||
| Sumant Kulkarni | Canaccord Genuity | $43→$24 | buy | 239.46%Upside | Reiterated | 07/27/26 | ||
| Tiago Fauth | Raymond James | $46 | buy | 550.64%Upside | Initiated | 06/25/26 | ||
| Paul Matteis | Stifel Nicolaus | $28→$36 | buy | 409.19%Upside | Reiterated | 06/02/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 05/14/26 | ||
| Marc Goodman | Leerink Partners | $30 | buy | 324.33%Upside | Initiated | 11/21/25 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Delma CaiatiGuggenheim | HoldInitiated | 10/05/26 | ― | ||
| Ami FadiaNeedham | BuyAssigned$45→$43 | 08/31/26 | 508.20%Upside | ||
| Sean LaamanMorgan Stanley | HoldAssigned$21 | 08/17/26 | 197.03%Upside | ||
| Francois BriseboisLifeSci Capital | BuyReiterated$37 | 08/14/26 | 423.34%Upside | ||
| Evan SeigermanBMO Capital | BuyReiterated$46→$20 | 08/13/26 | 182.89%Upside | ||
| Ashwani VermaUBS | HoldDowngraded$52→$13 | 08/11/26 | 83.88%Upside | ||
| Unknown AnalystJefferiesNot Ranked | BuyReiterated$25 | 07/30/26 | 253.61%Upside | ||
| Ram SelvarajuH.C. Wainwright | BuyReiterated$45→$26 | 07/28/26 | 267.75%Upside | ||
| Adam VogelCraig-Hallum | BuyReiterated$40→$25 | 07/28/26 | 253.61%Upside | ||
| Sumant KulkarniCanaccord Genuity | BuyReiterated$43→$24 | 07/27/26 | 239.46%Upside | ||
| Tiago FauthRaymond James | BuyInitiated$46 | 06/25/26 | 550.64%Upside | ||
| Paul MatteisStifel Nicolaus | BuyReiterated$28→$36 | 06/02/26 | 409.19%Upside | ||
| Joseph ThomeTD Cowen | BuyReiterated | 05/14/26 | ― | ||
| Marc GoodmanLeerink Partners | BuyInitiated$30 | 11/21/25 | 324.33%Upside |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering MapLight Therapeutics, Inc.
3 Months
Success Rate1/3 ratings generated profit
33%
Average Return
-3.97%
Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -3.97% per trade.
1 Year
Success Rate0/3 ratings generated profit
0%
Average Return
-54.47%
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -54.47% per trade.
2 Years
Success Rate0/3 ratings generated profit
0%
Average Return
-54.47%
Copying Sumant Kulkarni's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -54.47% per trade.
MPLT Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 13 | 12 | 10 | 3 | 0 |
| Buy | 19 | 12 | 6 | 0 | 0 |
| Hold | 1 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 33 | 27 | 19 | 6 | 1 |
In the current month, MPLT has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MPLT average Analyst price target in the past 3 months is 33.67.
MPLT Financial Forecast
MPLT Stock Forecast FAQ
What is MPLT’s average 12-month price target, according to analysts?
Based on analyst ratings, MapLight Therapeutics, Inc.’s 12-month average price target is $33.67.
What is MPLT’s upside potential, based on the analysts’ average price target?
MapLight Therapeutics, Inc. has 376.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MPLT a Buy, Sell or Hold?
MapLight Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.
What is MapLight Therapeutics, Inc.’s price target?
The average price target for MapLight Therapeutics, Inc. is $33.67. This is based on 4 12-month price targets, issued in the past 3 months. The highest analyst price target is $43.00, the lowest forecast is $21.00. The average price target represents a 376.19% increase from the current price of $7.07.
What do analysts say about MapLight Therapeutics, Inc.?
MapLight Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of MPLT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
